Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2010

01.04.2010 | Case Report

Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab

verfasst von: Amelia Troncoso Mariño, Eva Campelo Sánchez, Noemí Martínez López de Castro, María Teresa Inaraja Bobo

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Case A 44-year-old man was diagnosed with ankylosing spondylitis, on treatment with infliximab. After three doses, he was admitted to hospital with fever, fatigue and nausea. A bone marrow biopsy confirmed haemophagocytic syndrome. He was treated with immunoglobulin, cyclosporine and corticosteroids. CT scan revealed tuberculosis. Tuberculostatic treatment was started 26 days after admission. One month later, he was transferred intensive care with septic shock and acute respiratory distress syndrome. After improvement, he was transferred to the medical ward and later discharged. Two weeks after discharge, he was readmitted with a suspected paradoxical reaction (PR) to tuberculostatics and treated with prednisone. He was discharged 15 days later. Conclusions In patients treated with anti-TNF therapy it may be advisable to monitor the signs and symptoms of tuberculosis. HPS is a rare complication of rheumatic diseases. The possibility of developing a PR in immunosuppressed patients treated with antituberculous should be considered.
Literatur
1.
Zurück zum Zitat Kaene J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.CrossRef Kaene J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.CrossRef
2.
Zurück zum Zitat Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology. 2003;42:800–2.CrossRefPubMed Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology. 2003;42:800–2.CrossRefPubMed
3.
Zurück zum Zitat Onishi R, Namiuchi S. Hemophagocytic syndrome in a patient with rheumatoid arthritis. Intern Med. 1994;33:607–11.CrossRefPubMed Onishi R, Namiuchi S. Hemophagocytic syndrome in a patient with rheumatoid arthritis. Intern Med. 1994;33:607–11.CrossRefPubMed
4.
Zurück zum Zitat Artigues Barceló A, Ferragut Reus M, Sanchez C, Amengual I, Matanza I, Sanz Parras MS. Haemophagocytic syndrome and cutaneous T cell lymphoma. An Med Interna. 2004;21:131–4.PubMed Artigues Barceló A, Ferragut Reus M, Sanchez C, Amengual I, Matanza I, Sanz Parras MS. Haemophagocytic syndrome and cutaneous T cell lymphoma. An Med Interna. 2004;21:131–4.PubMed
5.
Zurück zum Zitat Breen RAM, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59:704–7.CrossRefPubMed Breen RAM, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59:704–7.CrossRefPubMed
6.
Zurück zum Zitat Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, et al. First update of the International ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316–20.CrossRefPubMed Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, et al. First update of the International ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316–20.CrossRefPubMed
7.
Zurück zum Zitat Descalzo MA, Comité Científico de BIOBADASER, Grupo de estudio BIOBADASER. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER). Informe diciembre 2006. Descalzo MA, Comité Científico de BIOBADASER, Grupo de estudio BIOBADASER. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER). Informe diciembre 2006.
8.
Zurück zum Zitat Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.CrossRefPubMed Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.CrossRefPubMed
9.
Zurück zum Zitat García Vidal C, Rodríguez Fernández S, Martínez Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756–9.CrossRefPubMed García Vidal C, Rodríguez Fernández S, Martínez Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756–9.CrossRefPubMed
Metadaten
Titel
Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab
verfasst von
Amelia Troncoso Mariño
Eva Campelo Sánchez
Noemí Martínez López de Castro
María Teresa Inaraja Bobo
Publikationsdatum
01.04.2010
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2010
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9369-x

Weitere Artikel der Ausgabe 2/2010

International Journal of Clinical Pharmacy 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.